In reply [7]

Journal of Clinical Oncology

Volumn 25, Issue 17, 2007, Pages 2494-2495

  Fröhling, Stefan ^a   Corbacioglu, Andrea ^a   Schlenk, Richard F ^a   Döhner, Hartmut ^a   Döhner, Konstanze ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN CEBPA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALLELE; CANCER; CANCER REGRESSION; CEBPA GENE; DNA SEQUENCE; GENE; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; LETTER; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 34347216036     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.1195     Document Type: Letter

References (6)

1. Frohling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
2. Lin LI, Chen CY, Lin DT, et al: Characterization of CEBPA mutations in acute myeloid leukemia: Most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11:1372-1379, 2005
3. Wouters BJ, Louwers I, Valk PJ, et al: A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109:389-390, 2007
4. Pabst T, Mueller BU, Zhang P, et al: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27:263-270, 2001
5. Estey E, Dohner H: Acute myeloid leukaemia. Lancet 368:1894-1907, 2006
6. Mrozek K, Dohner H, Bloomfield CD: Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: Recent advances. Curr Opin Hematol 14:106-114, 2007